N-(1,3-benzothiazol-2-yl)-N'-hydroxyhexanediamide | 1350909-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N-(1,3-benzothiazol-2-yl)-N'-hydroxyhexanediamide
• CAS: 1350909-27-1
• 化学式: C₁₃H₁₅N₃O₃S
• 分子量: 293.346
• InChiKey: JUMPHJFWBSDZDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 盐酸羟胺 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 N-(1,3-benzothiazol-2-yl)-N'-hydroxyhexanediamide
  参考文献：
  名称：

  Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents

  摘要：

  Data from clinical studies indicate that inhibitors of Class I and Class II histone deacetylase (HDAC) enzymes show great promise for the treatment of cancer. Zolinza (SAHA, Zolinza) was recently approved by the FDA for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma. As a part of our ongoing effort to identify novel small molecules to target these important enzymes, we have prepared two series of benzothiazole-containing analogues of SAHA. It was found that several compounds with 6C-bridge linking benzothiazole moiety and hydroxamic functional groups showed good inhibition against HDAC3 and 4 at as low as 1 mu g/ml and exhibited potent cytotoxicity against five cancer cell lines with average IC50 values of as low as 0.81 mu g/ml, almost equipotent to SAHA. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.07.124

文献信息

• Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents
  作者：Dao Thi Kim Oanh、Hoang Van Hai、Sang Ho Park、Hyun-Jung Kim、Byung-Woo Han、Hyung-Sook Kim、Jin-Tae Hong、Sang-Bae Han、Van Thi My Hue、Nguyen-Hai Nam

  DOI：10.1016/j.bmcl.2011.07.124

  日期：2011.12

  Data from clinical studies indicate that inhibitors of Class I and Class II histone deacetylase (HDAC) enzymes show great promise for the treatment of cancer. Zolinza (SAHA, Zolinza) was recently approved by the FDA for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma. As a part of our ongoing effort to identify novel small molecules to target these important enzymes, we have prepared two series of benzothiazole-containing analogues of SAHA. It was found that several compounds with 6C-bridge linking benzothiazole moiety and hydroxamic functional groups showed good inhibition against HDAC3 and 4 at as low as 1 mu g/ml and exhibited potent cytotoxicity against five cancer cell lines with average IC50 values of as low as 0.81 mu g/ml, almost equipotent to SAHA. (C) 2011 Published by Elsevier Ltd.